Literature DB >> 12410682

Squamous cell carcinoma in chronic lymphedema: case report and review of the literature.

Hiroshi Furukawa1, Yuhei Yamamoto, Hidehiko Minakawa, Tsuneki Sugihara.   

Abstract

BACKGROUND: Squamous cell carcinoma (SCC) arising in chronic lymphedema is rare; only nine cases have been reported.
OBJECTIVE: To present the evolution of SCC in chronic lymphedema.
METHODS: Case report and literature review.
RESULTS: The tumor was treated by wide excision and covered by a skin graft.
CONCLUSION: In most of the other reported SCC cases in lymphedema, there are additional factors for carcinogenesis. There is no additional carcinogenic factor except for chronic lymphedema in our case. This strongly supports that lymphedema itself is one of the carcinogenic factors for not only angiosarcoma but also SCC.

Entities:  

Mesh:

Year:  2002        PMID: 12410682     DOI: 10.1046/j.1524-4725.2002.02075.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  4 in total

Review 1.  Early diagnosis is vital in the management of squamous cell carcinomas associated with chronic non healing ulcers: a case series and review of the literature.

Authors:  Stuart Enoch; David R Miller; Patricia E Price; Keith G Harding
Journal:  Int Wound J       Date:  2004-09       Impact factor: 3.315

2.  Labia Majora Share.

Authors:  Hanjing Lee; Yan Lin Yap; Jeffrey Jen Hui Low; Jane Lim
Journal:  Arch Plast Surg       Date:  2017-01-20

3.  Squamous cell carcinoma of the penis and scrotum in a patient with chronic scrotal and penile lymphedema.

Authors:  Suhas V Abhyankar; Ananta Kulkarni; Madhuri Kulkarni; Naveen Kumar Agarwal
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

4.  Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation.

Authors:  Takayuki Kimura; Makoto Sugaya; Tomonori Oka; Andrew Blauvelt; Hitoshi Okochi; Shinichi Sato
Journal:  Oncotarget       Date:  2015-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.